More on Rifampin Prophylaxis against Haemophilus influenzae b in Day-Care Facilities

Claire V. Broome; Edward A. Mortimer; Samuel L. Katz; David W. Fleming; Allen W. Hightower; Michael T. Osterholm; Trudy V. Murphy

doi:10.1056/NEJM198801073180112

More on Rifampin Prophylaxis against Haemophilus influenzae b in Day-Care Facilities

Claire V. Broome, Edward A. Mortimer, Samuel L. Katz, David W. Fleming, Allen W. Hightower, Michael T. Osterholm, Trudy V. Murphy

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Abstract

To the Editor: A Special Report in the May 7 issue¹ by some of the members of the Immunization Practices Advisory Committee (ACIP) and staff members of the Centers for Disease Control, was not a formal statement by the ACIP. Rather, it was a discussion of the rationale for the ACIP's recommendations on the use of rifampin chemoprophylaxis for the prevention of secondary cases of Haemophilus influenzae b disease.¹ In that article we raised issues pertaining to the Minnesota and Texas studies²³ in an attempt to explain differences in the occurrence of secondary H. influenzae b disease in day-care facilities.

Original language	English (US)
Pages (from-to)	48-49
Number of pages	2
Journal	New England Journal of Medicine
Volume	318
Issue number	1
DOIs	https://doi.org/10.1056/NEJM198801073180112
State	Published - Jan 7 1988
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1056/NEJM198801073180112

Find It

Find It at U of M Libraries

Cite this

@article{7515874a45f24b678031dd27c573fe5f,

title = "More on Rifampin Prophylaxis against Haemophilus influenzae b in Day-Care Facilities",

abstract = "To the Editor: A Special Report in the May 7 issue1 by some of the members of the Immunization Practices Advisory Committee (ACIP) and staff members of the Centers for Disease Control, was not a formal statement by the ACIP. Rather, it was a discussion of the rationale for the ACIP's recommendations on the use of rifampin chemoprophylaxis for the prevention of secondary cases of Haemophilus influenzae b disease.1 In that article we raised issues pertaining to the Minnesota and Texas studies23 in an attempt to explain differences in the occurrence of secondary H. influenzae b disease in day-care facilities.",

author = "Broome, {Claire V.} and Mortimer, {Edward A.} and Katz, {Samuel L.} and Fleming, {David W.} and Hightower, {Allen W.} and Osterholm, {Michael T.} and Murphy, {Trudy V.}",

year = "1988",

month = jan,

day = "7",

doi = "10.1056/NEJM198801073180112",

language = "English (US)",

volume = "318",

pages = "48--49",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "1",

}

TY - JOUR

T1 - More on Rifampin Prophylaxis against Haemophilus influenzae b in Day-Care Facilities

AU - Broome, Claire V.

AU - Mortimer, Edward A.

AU - Katz, Samuel L.

AU - Fleming, David W.

AU - Hightower, Allen W.

AU - Osterholm, Michael T.

AU - Murphy, Trudy V.

PY - 1988/1/7

Y1 - 1988/1/7

N2 - To the Editor: A Special Report in the May 7 issue1 by some of the members of the Immunization Practices Advisory Committee (ACIP) and staff members of the Centers for Disease Control, was not a formal statement by the ACIP. Rather, it was a discussion of the rationale for the ACIP's recommendations on the use of rifampin chemoprophylaxis for the prevention of secondary cases of Haemophilus influenzae b disease.1 In that article we raised issues pertaining to the Minnesota and Texas studies23 in an attempt to explain differences in the occurrence of secondary H. influenzae b disease in day-care facilities.

AB - To the Editor: A Special Report in the May 7 issue1 by some of the members of the Immunization Practices Advisory Committee (ACIP) and staff members of the Centers for Disease Control, was not a formal statement by the ACIP. Rather, it was a discussion of the rationale for the ACIP's recommendations on the use of rifampin chemoprophylaxis for the prevention of secondary cases of Haemophilus influenzae b disease.1 In that article we raised issues pertaining to the Minnesota and Texas studies23 in an attempt to explain differences in the occurrence of secondary H. influenzae b disease in day-care facilities.

UR - http://www.scopus.com/inward/record.url?scp=0023832218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023832218&partnerID=8YFLogxK

U2 - 10.1056/NEJM198801073180112

DO - 10.1056/NEJM198801073180112

M3 - Letter

C2 - 3257291

AN - SCOPUS:0023832218

SN - 0028-4793

VL - 318

SP - 48

EP - 49

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 1

ER -

More on Rifampin Prophylaxis against Haemophilus influenzae b in Day-Care Facilities

Abstract

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this